

What is claimed is:

1. A method for treatment of advanced cutaneous T cell lymphoma in a human comprising administering to a human an effective amount of recombinant interleukin-12 in a pharmaceutically acceptable carrier.

B3
2. The method of claim 1 further comprising administering an adjunct therapeutic agent which stimulates interferon- γ production.

Suba
3. A composition for treatment of advanced cutaneous T cell lymphoma in a human comprising recombinant interleukin-12 and an adjunct therapeutic agent which stimulates interferon- γ production.